麻醉类药、精神病类药的质量检测以及处方管理

生物测定是经典的药品检测专业之一，现代仪器分析的广泛应用，给其带来了极大的挑战和机遇，面对目前的基本状况，阐明了生物测定专业在中药开发、新药研制、药物安全性评价及微生物限度检查方面的应用和发展趋势。探讨了麻醉药、精神病类药的质量检测及处方管理，并对加强我国药品生产质量监管提出了一些建议。

苯甲酰胺类抗精神病药物的归类和构效研究

目的:对苯甲酰胺类抗精神病药的结构、归类及构效关系进行研究。方法:通过对其化学结构进行比对研究,从分子层面寻找其结构与分类及构效关系。结果:苯甲酰胺类抗精神病药在临床作用、结构、递质作用方面与第一代抗精神病药多有不符;其结构上最具共性的结构是邻茴酰胺基;其苯环5位的磺酰基和N-乙基-2-氨甲基吡咯抗精神病活性作用较强。结论:这类药应归为第二代抗精神病药,称为邻茴酰胺类更能体现其结构共性。其苯环5位的磺酰基和N-乙基-2-氨甲基吡咯有较强的抗精神病活性作用。

酚噻嗪类抗精神病药所致的心电图异常(摘要)

对639例住院精神病患者进行心电图检查,发现心电图异常223例,占34.9%。全部病例均接受酚噻嗪类药治疗.治疗前心电图正常。按住院时间长短分为两组:短期组(住院两个月至1年)432例、心电图异常112例(25.9%);长期组(住院超过1年)207例,心电图异常111例(53.6%)。

药物性帕金森综合征研究进展

帕金森综合症发病率逐年上升,其中药物是造成帕金森综合症最常见原因之一,本文对几类常见、易引发药物性帕金森综合症的药物进行了分析.

The Therapeutic Effects of Ling Gui Zhu Gan Tang Mixture in 50 Psychotic Patients with Obesity Induced by the Psychoactive Drugs

In order to observe the therapeutic effects of Ling Gui Zhu Gan Tang Mixture (芩桂术甘汤) on obesity induced by psychoactive drugs, 100 psychotics with obesity induced by psychoactive drugs were randomly divided into a treatment group (50 cases)and a control group (50 cases) for a 8-week treatment.The changes were determined by means of the Brief Psychiatric Rating Scale (BPRS) and the Treatment Emergent Symptom Scale (TESS) with the body weight recorded before and after treatment. The results showed that the total effective rate was 72% in the treatment group, and 14% in the control group,with the former obviously superior to the latter (P＜0.01). The BPRS scores were 33.02t7.34 in the treatment group and 32.39± 3.51 in the control group before treatment; and 20.38±5.10 in the treatment group and 20.82± 1.75 in the control group after treatment. The BPRS scores were obviously reduced after treatment in the two groups (both P＜0.01), but with no significant difference between the two groups (P＞0.05). This indicates that the Ling Gui Zhu Gan Tang Mixture does not influence the curative effect of the psychoactive drugs while showing the body weight-reducing effect. Therefore, the Ling Gui Zhu Gan Tang Mixture can be used for those psychotic patients with obesity induced by the psychoactive drugs (the incidence is 10-25%) in their continuous course of treatment with the latter drugs.

Novartis公司撤回Melleril

Novartis公司已决定自7月1日起在全世界停止销售其吩噻嗪类抗精神病药Melleril(thioridazine，硫利达嗪)(Ⅰ)，因为其风险利益比不再被认为是肯定的。(Ⅰ)是上世纪50年代后期上市的，适用于慢性精神分裂症或急性精神病成年人，不作为一线药使用。

HPLC法测定盐酸硫利达嗪片的有关物质及含量

目的：建立RP-HPLC法测定盐酸硫利达嗪片中有关物质及含量。方法：采用Diamonsil C18（150 mm×4.6 mm,5μm）色谱柱;含量测定以乙腈-水-三乙胺（850∶150∶1）为流动相,流速1 m L·min-1,检测波长264 nm,柱温40℃;以外标法对含量进行测定。有关物质测定以三乙胺-乙腈-水（2∶400∶600）为流动相A,三乙胺-乙腈（2∶1 000）为流动相B,梯度洗脱（0~5 min,100%A;5~35 min,100%A→5%A;35~40 min,5%A;40~41 min,5%A→100%A;41~46 min,100%A）,流速1 m L·min-1,检测波长275 nm,柱温40℃;以主成分自身对照法对有关物质进行定量测定。结果：在选定的色谱条件下,盐酸硫利达嗪和有关物质完全分离;辅料对主成分的含量测定无干扰;盐酸硫利达嗪在50~500μg·m L-1范围内线性关系良好,相关系数r为0.999 8;低、中、高3种浓度的平均回收率分别为100.6%、100.0%、99.81%,RSD分别为1.5%、1.9%、0.8%。3批样品中主成分含量分别为101.7%、97.3%、108.0%;单个杂质限量定为0.5%,杂质总量为1.0%。结论：本法经方法学验证,可用于盐酸硫利达嗪片的有关物质检查和含量测定。